| 摘要 |
591525 Disclosed is the use of oritavancin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent for the manufacture of a medicament for the complete and effective treatment of complicated skin and skin structure infection (cSSSI) in a subject, wherein the medicament is formulated to comprise at least about 900 mg of oritavancin, or a pharmaceutically acceptable salt thereof, and be administered to the subject in one dose over the course of therapy to thereby treat the bacterial infection. |
